Gastric Cancer Stage IV
Conditions
Brief summary
In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node \[LN\]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).
Interventions
DRUGimmune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Stage IV gastric cancer patients who underwent conversion surgery
Exclusion criteria
* Patients who did not undergo gastrectomy * Patients who underwent emergent surgery due to cancer perforation * Patients with missing medical records or information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival and disease free survival | from date of surgery until the date of first documented cancer recurrence or date of death from cancer progression, whichever came first, assessed up to 160 months |
Outcome results
None listed